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EGF is unique among angiogenic growth factors
because it disrupts endothelial barrier function.
Therefore, we considered whether this property
of VEGF might contribute to tumor cell extravasation and
metastasis. To test this, mice lacking the Src family kinases
Src or Yes, which maintain endothelial barrier function
in the presence of VEGF, were injected intravenously
with VEGF-expressing tumor cells. We found a dramatic
reduction in tumor cell extravasation in lungs or livers of
mice lacking Src or Yes. At the molecular level, VEGF
compromises the endothelial barrier by disrupting a
V
 
VE-cadherin–
 
 
 
-catenin complex in lung endothelium
from wild-type, but not Yes-deﬁcient, mice. Disrupting the
endothelial barrier directly with anti–VE-cadherin both
ampliﬁes metastasis in normal mice and overcomes the
genetic resistance in Yes-deﬁcient mice. Pharmacological
blockade of VEGF, VEGFR-2, or Src stabilizes endothelial
barrier function and suppresses tumor cell extravasation
in vivo. Therefore, disrupting Src signaling preserves host
endothelial barrier function providing a novel host-targeted
approach to control metastatic disease.
 
Introduction
 
Hematogenous metastasis is a complex cascade involving tumor
cell invasion from the primary tumor, intravasation into the
circulation, as well as extravasation at distant sites. The molec-
ular mechanisms regulating tumor cell extravasation in vivo
are poorly understood, but clearly depend on the invasive
capacity of tumor cells and their ability to breach the endothelial
cell barrier. Because VEGF has been implicated in the break-
down of endothelial cell barrier function through disruption of
adherens junctions (Esser et al., 1998), the production and
release of VEGF by tumor cells (Senger et al., 1993) may con-
tribute to their extravasation and metastasis.
Recently, we demonstrated that VEGF leads to vascular
permeability in a manner that depends on Src family kinases
(Eliceiri et al., 1999). Although endothelial cells express three
primary Src family members (Src, Fyn, and Yes), only mice
deficient in Src or Yes are protected from VEGF-induced per-
meability, yet show normal angiogenesis (Eliceiri et al., 1999).
This selective resistance to VEGF-induced permeability pro-
tects Src- or Yes-deficient mice from cardiac (Weis et al.,
2004) or cerebral (Paul et al., 2001) edema after ischemic
injury. The fact that these mice lack a VEGF-mediated perme-
ability response allows us to determine whether VEGF facili-
tates tumor cell extravasation during the spread of metastatic
tumor cells. Here, we use various models of experimental
metastasis in which intravenously injected VEGF-expressing
tumor cells colonize the lung or liver. These models allow for
investigation of the extravasation of circulating tumor cells
regardless of their ability to proliferate and migrate at the
primary tumor site. Here, we demonstrate that VEGF-mediated
Src kinase activity leads to a breakdown in endothelial barrier
function which, in turn, hastens tumor cell extravasation and
metastasis. In fact, both genetic and pharmacological evidence
is presented indicating that blockade of endothelial cell Src
activity increases host resistance to metastatic disease.
 
Results and discussion
 
Ultrastructural analysis of tumor cell 
extravasation
 
To study the extravasation phase of metastasis, we injected
VEGF-expressing CT26 murine colon carcinoma cells i.v. into
mice and evaluated the lungs from these animals at the ultra-
structural level after hours to days. In normal mice 1–3 h after
inoculation, CT26 cells can be observed extending processes
between gaps in the endothelium (Fig. 1, A and B), suggesting
that a breach in endothelial barrier function may facilitate
extravasation. In fact, single cells extravasate within hours of
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entering the circulation (Fig. 1 C), and form multicellular le-
sions after several days (Fig. 1 D). These studies suggest the
possibility that VEGF, which induces such endothelial gaps
(Weis et al., 2004), may facilitate tumor cell extravasation.
 
VEGF expression enhances lung 
colonization of ovarian tumor cells
 
To evaluate the possibility that endothelial barrier breakdown
by VEGF contributes to tumor cell extravasation, we tested
ID8 murine ovarian carcinoma cells retrovirally infected to sta-
bly express GFP either alone or together with VEGF (Zhang et
al., 2002). ID8 cells overexpressing VEGF were previously
found to have a metastatic advantage compared with ID8 cells
lacking VEGF (Zhang et al., 2002), but it was unclear whether
tumor cell extravasation was enhanced. Accordingly, ID8 cells
were injected i.v. into the tail vein and tumor metastasis was
monitored 9 d later. The VEGF-expressing ID8 cells formed
considerably more metastatic lesions in the lung than the cells
expressing GFP alone (Fig. 2), suggesting that VEGF contrib-
utes to tumor cell extravasation and/or cell proliferation at the
metastatic site. Together, these studies suggest that tumor cell
extravasation is linked to the ability of VEGF to promote a
breakdown in endothelial barrier function.
 
Mice deficient in Src or Yes are 
protected from tumor cell extravasation
 
We demonstrated previously that Src- or Yes-deficient mice or
normal mice treated with pharmacological Src inhibitors fail to
undergo VEGF-dependent vascular permeability yet show nor-
mal VEGF-mediated angiogenesis (Eliceiri et al., 1999). Thus,
Figure 1. Tumor cell accumulation hours-
to-days after tumor cell injection. To determine
a time line for CT26 tumor cell extravasation
after i.v. inoculation, we prepared lungs for
analysis by transmission EM. By 1–3 h, tumor
cells (T) had extended protrusions toward
endothelial cells (EC) (A) or extended processes
between EC junctions to contact the under-
lying basal lamina (BL) (B). (C) At 3 h, we
observed individual extravasated tumor cells
immediately outside the blood vessels where
they were typically lodged in the extracellular
space between an EC and a pneumocyte
(PC). (D) This ultimately gave way to meta-
static foci containing numerous tumor cells by
day 4. Bars: (A–C) 1  m; (D) 5  m. 
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these mice allow us to evaluate the role that VEGF-mediated
vascular permeability plays in tumor cell extravasation in vivo.
Src- or Yes-deficient mice showed significantly diminished
CT26 or D121 Lewis Lung carcinoma metastatic lesions in the
lung compared with wild-type littermates (Fig. 3, A–C). In a
second metastatic model, CT26 or D121 cells were injected be-
neath the spleen capsule followed by splenectomy, which ulti-
mately results in hepatic metastatic lesions (Xiang et al., 1997).
Consistent with the lung model, Yes-deficient mice showed
sharply reduced hepatic metastases compared with control ani-
mals for either cell line (Fig. 3 D).
Importantly, primary tumor growth of each cell line in-
jected subcutaneously on the flank was identical for wild-type
and Yes-deficient mice (Fig. 3 E) indicating that these animals
have no intrinsic defect in angiogenesis or tumor growth per se.
Furthermore, mice lacking the Src family kinase Fyn, which
show normal VEGF-induced vascular permeability (Eliceiri et
al., 1999), are not resistant to pulmonary metastasis (Fig. 3 F).
These findings demonstrate Src- or Yes-, but not Fyn-deficient
mice, which show no VEGF-induced permeability are geneti-
cally resistant to the extravasation phase of metastasis. These
findings confirm that there is specificity among the ubiqui-
tously expressed Src family kinase members (Src, Fyn, and
Yes), and reinforces the causal link between vascular perme-
ability and tumor cell extravasation.
 
Src kinase regulation of VE-cadherin–
 
 
 
-
catenin association facilitates tumor cell 
extravasation
 
Recently, we showed that during ischemic injury, VEGF-
mediated vascular permeability depends on Src kinase-
induced uncoupling of VE-cadherin–
 
 
 
-catenin containing
junctions in vivo (Weis et al., 2004). Therefore, we evalu-
ated the possibility that VEGF-expressing tumor cells circu-
lating in the lung may compromise the vascular barrier by
disrupting the VE-cadherin–
 
 
 
-catenin complex within the
lung vasculature. Mice were injected i.v. with VEGF and
lung lysates were subjected to immunoprecipitation and im-
munoblotting to detect the VE-cadherin–
 
 
 
-catenin complex.
5 min after VEGF stimulation, we observed a transient but
consistent decrease in the lung endothelial cell VE-cadherin–
 
 
 
-catenin complex (Fig. 4 A). In contrast, this VE-cadherin–
 
 
 
-catenin complex did not dissociate after VEGF treatment
in Yes-deficient mice (Fig. 4 A), which are resistant to the
permeability-promoting effects of VEGF (Eliceiri et al.,
1999) and to tumor cell extravasation (Fig. 3 A). These data
not only confirm a role for Src kinases downstream of VEGF
in the regulation of cadherin-mediated endothelial junctional
barrier function, but help to explain the resistance these ani-
mals display toward tumor cell extravasation.
 
Perturbation of VE-cadherin–mediated 
intercellular adhesion enhances tumor 
cell extravasation
 
To determine whether disruption of VE-cadherin was suffi-
cient to promote tumor cell extravasation and metastasis, we
evaluated the metastatic capacity of circulating CT26 cells in
animals whose endothelial barrier function was compromised
by a function blocking antibody to VE-cadherin (BV13).
Treatment of these animals with BV13, which is known to
disrupt endothelial barrier function of normal vessels (Liao et
al., 2002), dramatically increased pulmonary metastasis of
CT26 tumor cells by four- to sevenfold (Fig. 4 B) compared
with mice treated with either saline or the isotype matched
anti–VE-cadherin mAb E4G10. E4G10 serves as a strong
control, because like BV13, it recognizes an epitope on the
extracellular domain of VE-cadherin, but unlike BV13 does
not disrupt endothelial barrier function (Liao et al., 2002).
The ratio of wet/dry lung weight was not different between
mice treated with BV13 or vehicle for 24 h (4.64 
 
 
 
 0.04 and
Figure 2. VEGF-expressing tumor cells show enhanced metastasis. ID8
murine ovarian carcinoma cells, which stably express GFP, were injected
i.v. to form pulmonary metastatic lesions. (A) Fresh lung tissue was examined
using laser scanning confocal microscopy to detect GFP-positive metastatic
tumor cells. After 9 d, considerably more metastatic lesions were visible
in lungs of mice injected with cells expressing VEGF (ID8-VEGF-GFP)
compared with cells expressing GFP alone (ID8-GFP). (B) Lung weight due
to tumor was significantly increased. * indicates P   0.05; n   8 each
bar. Bar, 1 mm. 
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4.69 
 
 
 
 0.00, respectively), demonstrating the increase in lung
weight is due to tumor, not edema. Although both BV13
and E4G10 block angiogenesis and suppress primary tumor
growth (Liao et al., 2002), our findings demonstrate that dis-
ruption of VE-cadherin–mediated intercellular junctions with
BV13 is sufficient to promote tumor cell extravasation, sug-
gesting that VE-cadherin adhesion and its regulation of endo-
thelial barrier function plays a role as a “gatekeeper” in the
metastatic cascade.
To establish whether the suppression of metastasis in
Yes-deficient mice is related to VE-cadherin–dependent bar-
rier function, these animals were treated with the VE-cad-
herin function blocking antibody BV13. This resulted in a
fourfold increase (P
 
   
 
0.006) in the number of metastatic le-
sions within the lungs of these animals, and a 27 
 
 
 
 4% in-
crease (P 
 
  
 
0.0001) in lung weight due to tumor compared
with untreated Yes-deficient mice (
 
n 
 
  
 
8 each group). There-
fore, disruption of VE-cadherin can overcome the genetic re-
sistance to tumor cell extravasation observed in Yes-deficient
mice, supporting the notion that Src kinase regulation of VE-
cadherin within the endothelium impacts tumor cell extrava-
sation in vivo.
 
VEGF, Flk, or Src inhibitors suppress 
tumor cell extravasation
 
If VEGF signaling potentiates endothelial barrier breakdown,
then pharmacological blockade of VEGF or its downstream ef-
fectors might reduce tumor cell extravasation. Thus, we tested
if blocking VEGF signaling during the first 2 d after i.v. admin-
istration of tumor cells would impact extravasation. We found
that treating mice with the VEGF inhibitor Cyclo-VEGI re-
duced pulmonary metastasis by 47% (Fig. 5 A, P 
 
  
 
0.01), sug-
gesting that an early step in tumor cell extravasation is sensi-
tive to pharmacological inhibition of VEGF.
Although VEGF signaling occurs through binding to its
three cell surface receptors VEGFR-1 (Flt), VEGFR-2 (Flk/
KDR), and/or neuropilin1/2, the permeability-inducing effects
of VEGF have been attributed to signaling downstream of Flk
exclusively (Ferrara et al., 2003). Therefore, we considered
whether blockade of Flk might influence tumor cell extravasa-
tion and the number or size of metastatic lesions in the CT26 ex-
perimental pulmonary metastasis model. Mice were pretreated
with a single injection of a Flk inhibitor (SU1498) 1 h before i.v.
inoculation with CT26 cells. This treatment reduced lung me-
tastasis by 
 
 
 
50% (Fig. 5 B, P 
 
  
 
0.001), suggesting that Flk-
Figure 3. Gene-targeted deletion of individual
Src kinases protects against tumor cell extra-
vasation. (A–C) Tumor burden, computed as
the increase in lung/heart weight ratio over
that for normal mice, was measured 12 d after
i.v. inoculation with metastatic tumor cells.
Mice lacking Src (A) or Yes (B and C) are pro-
tected from experimental pulmonary metastasis
of CT26 (A and B) or D121 (C) cells. (D) This
phenomenon is not specific to the lung, because
Yes-deficient mice are also protected from
experimental hepatic metastasis of CT26 or
D121 cells. (E) Growth of primary tumors on
the flank is not different between genotypes
for CT26 or D121 cells. (F) Mice lacking Fyn,
which show a normal vascular permeability
response to VEGF, are not protected from
metastasis. * indicates P   0.05; n   8 each
bar. Bar, 1 mm. 
SRC KINASES IN TUMOR CELL EXTRAVASATION • WEIS ET AL.
 
227
 
dependent signaling during the dissemination phase of metasta-
sis contributes to disease progression. Although this particular Flk
inhibitor has recently been shown to affect Erk signaling down-
stream of other growth factors (Boguslawski et al., 2004), the
efficacy of a single dose of this agent delivered before tumor
cell inoculation is consistent with the blockade of VEGF-medi-
ated tumor cell extravasation during the hours after injection.
We previously demonstrated that Src activity is required
downstream of VEGF for subsequent VE-cadherin and 
 
 
 
-cate-
nin phosphorylation, leading to breakdown of endothelial bar-
rier function (Weis et al., 2004). Thus, we considered whether
a pharmacological Src inhibitor might suppress tumor cell ex-
travasation and metastasis in genetically normal mice. Admin-
istration of the Src inhibitor SKI-606 at the minimal dose re-
quired to block vascular leak (Fig. 5 C, 10 mg/kg) during the
first 3 d after either CT26 or D121 tumor cell inoculation re-
duced the formation of metastatic lesions in the lung by nearly
60% (Fig. 5 D), yet did not influence proliferation of these cells
in culture (not depicted). SKI-606 like other inhibitors is likely
to target a number of structurally related kinases and may di-
rectly impact tumor cell activities associated with invasion
(Golas et al., 2003; Recchia et al., 2003). Nevertheless, consid-
ering the genetic data, it appears that Src kinases may be im-
Figure 4. Disruption of cadherin-mediated adhesion enhances tumor cell
extravasation. (A) Direct i.v. injection of VEGF induces rapid and transient
dissociation of  -catenin from VE-cadherin in lung from wild-type, but not
Yes-deficient mice, determined by immunoprecipitation and immuno-
blotting of mouse lung homogenates. Representative data from three
experiments are shown. (B) Treating mice before tumor cell inoculation
with VE-cadherin–disrupting antibody BV13 induces vascular permeability,
facilitates CT26 tumor cell extravasation, and increases metastases. VE-
cadherin antibody E4G10 which does not produce permeability has no
impact on metastasis. Tumor burden represents increase in lung/heart
weight ratio over control. * indicates P   0.05; n   8 each bar (A) and
n   4 each bar (B).
Figure 5. Pharmacological Src, Flk, or VEGF blockade suppresses tumor
cell extravasation. (A) Pretreatment with VEGF inhibitor Cyclo-VEGI provides
a similar extent of protection from pulmonary metastases as Src or Flk
inhibition, further suggesting the permeability-inducing effects of VEGF
contribute to tumor cell extravasation. (B) VEGF receptor 2 signaling is
required for metastasis of CT26 cells because a single pretreatment with
Flk inhibitor SU1498 reduces lung tumor burden after 12 d. (C) Pretreatment
with Src inhibitor provides a dose-dependent blockade of VEGF-induced
vascular leak in the skin evaluated using the Miles assay. (D) Src inhibitor
treatment administered twice daily during days 0–3 after i.v. introduction
of CT26 or D121 cells significantly reduces lung tumor burden after 12 d.
(E) Preventing VEGF-induced endothelial barrier breakdown via VEGF,
Flk, or Src blockade preserves cadherin-mediated endothelial cell adhe-
sion and limits tumor cell extravasation. Tumor burden represents mean  
SEM for increase in lung/heart weight ratio over control. * indicates P  
0.05; n   8 each bar (A, B, and D); n   4 each bar (C). 
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portant targets to regulate host endothelial barrier function dur-
ing metastatic disease.
Together, these data suggest that disrupting VEGF sig-
naling leading to vascular leak by pretreatment with pharmaco-
logical inhibitors of VEGF, Flk, or Src can alleviate lung me-
tastasis (Fig. 5 E). The beneficial effect of these inhibitors was
attained by treatment within the first few days after tumor cell
inoculation when single tumor cells are beginning to extrava-
sate and proliferate, but before tumor growth and angiogenesis
is established.
 
Conclusions
 
Previous studies have implicated VEGF (Rowe et al., 2000),
Flk (Bruns et al., 2002), or Src (Golas et al., 2003) in tumor
growth and metastatic disease. In particular, blockade of tumor
cell-associated Src activity has been associated with reduced
metastasis (Nam et al., 2002), but this has been attributed to the
requirement of Src activity for tumor cell migration and intra-
vasation into the circulation from the primary tumor site. We
demonstrate for the first time that regardless of the invasive ca-
pacity of individual tumor cells, metastatic disease critically
depends on the ability of circulating tumor cells to breach the
endothelial barrier. We propose that metastatic tumor cells
which express and release high levels of VEGF have the capac-
ity to dysregulate at least one critical endothelial cell–cell junc-
tional complex facilitating their extravasation. These findings
suggest an unexpected therapeutic role for pharmacological in-
hibitors of VEGF or Src kinases in blocking a host response
important for metastatic disease.
 
Materials and methods
 
Pharmacological agents
 
The SKI-606 Src inhibitor (10 mg/kg i.p., 236 nM; Boschelli et al., 2001;
Golas et al., 2003) was injected twice daily for days 0–3 after tumor cell
injection. The SU1498 Flk inhibitor (single injection 1 h before tumor cell
injection, 20 mg/kg i.p., 385 nM) and Cyclo-VEGI (CBO-P11) VEGF in-
hibitor (twice daily days 0–2 after tumor cell injection, 2 mg/kg i.p., 13
nM) were purchased from Calbiochem. VE-cadherin murine mAbs BV13
and E4G10 (Liao et al., 2000, 2002), gifts from D. Hicklin (ImClone Sys-
tems, Inc.), were injected i.p. at 50 
 
 
 
g per adult mouse 1 h before tumor
cell injection.
 
Cell culture
 
ID8 murine ovarian carcinoma cells retrovirally infected to stably express
GFP or GFP
 
 
 
VEGF were provided by G. Coukos (University of Pennsylva-
nia, Philadelphia, PA) and have been described previously (Zhang et al.,
2002). Murine CT26 colon carcinoma and D121 Lewis Lung carcinoma
cells were provided by R. Reisfeld at our institution. Cells were maintained
at subconfluency, washed, harvested, counted, and resuspended in sterile
PBS for tumor cell injection as described previously (Hood et al., 2002;
Zhang et al., 2002).
 
Mice
 
Mice with gene-targeted deletion of Src, Yes, or Fyn are available from
Jackson Laboratory. Src- and Yes-deficient mice were the gifts of P. Sori-
ano and J. Cooper (Fred Hutchinson Cancer Research Center, Seattle,
WA), and P. Stein (University of Pennsylvania, Philadelphia, PA). BalbC
and C57By/J mice were generated at The Scripps Research Institute. Ap-
propriate age-matched littermate wild-type controls were used for each
gene-targeted strain.
 
Experimental metastasis
 
We injected 5 
 
 
 
 10
 
5
 
 CT26, D121, or ID8 carcinoma cells either i.v. (for
experimental pulmonary metastasis) or beneath the spleen capsule fol-
lowed by its removal within 2 min (for experimental hepatic metastasis),
typically resulting in the formation of lung or liver metastases, respectively,
within 4 d (Xiang et al., 1997). Metastases were established for 12 d to
ensure that all control animals contained actively growing lung or liver tu-
mors of a consistent size. Fresh tissue was photographed using an re-
search stereoscope (model SZH10; Olympus) with a SPOT camera (model
2.2.1; Diagnostic Instruments) or a laser scanning confocal microscope
(emission filter 522 nm for GFP, 2.5
 
 
 
/0.075, MRC 1024; Bio-Rad Labo-
ratories). Tissue was weighed and images were acquired using an BX60
light microscope (Olympus) with UPlanFI (10
 
 
 
/0.30) or UPlanApo (20
 
 
 
/
0.70) objectives and a SPOT camera (model 2.2.1; Diagnostic Instru-
ments). To account for differences between mice of different age, gender,
or genotype, lung tumor burden was computed as the increase in the ratio
of lung/heart weight over control mice (1.43 
 
 
 
 0.06 g for 31 mice). In
some groups, tissue was fixed, sectioned, and stained with hematoxylin
and eosin to count the number of lesions per section of equivalent area.
Data in each figure are representative of three or more separate experi-
ments, each performed with appropriate littermate controls.
 
Primary tumor growth
 
CT26 (5 
 
 
 
 10
 
5
 
) or D121 (10
 
5
 
) carcinoma cells were injected subcutane-
ously on the mouse flank, and growth of the primary tumor was measured
by microcaliper for 14 d. Tumor volume (V) was computed as V 
 
 
 
 1/2
(L 
 
 
 
 W)
 
2
 
, where L and W represent tumor width (shortest dimension) and
length (longest dimension), respectively.
 
Ultrastructural analysis by electron microscopy
 
Tissue was prepared from mouse lung 1 h to 4 d after CT26 tumor cell in-
jection. Tissue was prepared as described previously (Weis et al., 2004)
and ultra thin sections were viewed using a CM-100 transmission electron
microscope (Philips). Negatives were scanned on an Epson Expression
1680 scanner using Adobe Photoshop 7.0 software.
 
In vivo vascular permeability
 
The Miles assay was adapted to measure local VEGF-induced leak of dye
in the skin as described previously (Eliceiri et al., 1999).
 
In vivo vascular signaling
 
Adult mice were injected i.v. with 100 
 
 
 
l of VEGF (0.2 mg/kg in PBS;
PeproTech). At specified times, the lungs were rapidly excised, homoge-
nized, and prepared for immunoprecipitation and immunoblotting as de-
scribed previously (Weis et al., 2004). The following antibodies were
purchased from Santa Cruz Biotechnology: VE-cadherin (SC-6458) and
 
 
 
-catenin (SC-7963). Representative data from at least three separate ex-
periments are shown.
 
Statistical analysis
 
Data are presented as mean 
 
  
 
SEM, with statistical significance deter-
mined from 
 
t
 
 test (P 
 
  
 
0.05).
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